Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience

Intravascular large B‐cell lymphoma (IVLBCL) is a rare subtype of B‐cell lymphoma characterized by aggressive disease progression with a high incidence of central nervous system (CNS) involvement. We retrospectively analyzed 16 patients with de novo IVLBCL treated at our hospital between 2004 and 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Hiromichi, Nishimaki, Haruna, Nakanishi, Yoko, Hamada, Takashi, Nakagawa, Masaru, Iizuka, Kazuhide, Uchino, Yoshihito, Iriyama, Noriyoshi, Miura, Katsuhiro, Nakayama, Tomohiro, Masuda, Shinobu, Hatta, Yoshihiro, Nakamura, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176124/
https://www.ncbi.nlm.nih.gov/pubmed/35846032
http://dx.doi.org/10.1002/jha2.380
_version_ 1784722596164534272
author Takahashi, Hiromichi
Nishimaki, Haruna
Nakanishi, Yoko
Hamada, Takashi
Nakagawa, Masaru
Iizuka, Kazuhide
Uchino, Yoshihito
Iriyama, Noriyoshi
Miura, Katsuhiro
Nakayama, Tomohiro
Masuda, Shinobu
Hatta, Yoshihiro
Nakamura, Hideki
author_facet Takahashi, Hiromichi
Nishimaki, Haruna
Nakanishi, Yoko
Hamada, Takashi
Nakagawa, Masaru
Iizuka, Kazuhide
Uchino, Yoshihito
Iriyama, Noriyoshi
Miura, Katsuhiro
Nakayama, Tomohiro
Masuda, Shinobu
Hatta, Yoshihiro
Nakamura, Hideki
author_sort Takahashi, Hiromichi
collection PubMed
description Intravascular large B‐cell lymphoma (IVLBCL) is a rare subtype of B‐cell lymphoma characterized by aggressive disease progression with a high incidence of central nervous system (CNS) involvement. We retrospectively analyzed 16 patients with de novo IVLBCL treated at our hospital between 2004 and 2018 with either standard therapy plus CNS‐directed therapy or standard therapy alone. CNS‐directed therapy was associated with a significantly better 2‐year CNS‐free survival (100% vs. 63%, p = 0.0191), despite no significant effects on progression‐free or overall survival. Further studies should assess CNS‐focused treatment in patients with IVLBCL with or without primary CNS involvement.
format Online
Article
Text
id pubmed-9176124
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91761242022-07-14 Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience Takahashi, Hiromichi Nishimaki, Haruna Nakanishi, Yoko Hamada, Takashi Nakagawa, Masaru Iizuka, Kazuhide Uchino, Yoshihito Iriyama, Noriyoshi Miura, Katsuhiro Nakayama, Tomohiro Masuda, Shinobu Hatta, Yoshihiro Nakamura, Hideki EJHaem Short Reports Intravascular large B‐cell lymphoma (IVLBCL) is a rare subtype of B‐cell lymphoma characterized by aggressive disease progression with a high incidence of central nervous system (CNS) involvement. We retrospectively analyzed 16 patients with de novo IVLBCL treated at our hospital between 2004 and 2018 with either standard therapy plus CNS‐directed therapy or standard therapy alone. CNS‐directed therapy was associated with a significantly better 2‐year CNS‐free survival (100% vs. 63%, p = 0.0191), despite no significant effects on progression‐free or overall survival. Further studies should assess CNS‐focused treatment in patients with IVLBCL with or without primary CNS involvement. John Wiley and Sons Inc. 2022-02-02 /pmc/articles/PMC9176124/ /pubmed/35846032 http://dx.doi.org/10.1002/jha2.380 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Takahashi, Hiromichi
Nishimaki, Haruna
Nakanishi, Yoko
Hamada, Takashi
Nakagawa, Masaru
Iizuka, Kazuhide
Uchino, Yoshihito
Iriyama, Noriyoshi
Miura, Katsuhiro
Nakayama, Tomohiro
Masuda, Shinobu
Hatta, Yoshihiro
Nakamura, Hideki
Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience
title Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience
title_full Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience
title_fullStr Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience
title_full_unstemmed Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience
title_short Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience
title_sort clinical impact of central nervous system‐directed therapies on intravascular large b‐cell lymphoma: a single institution's experience
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176124/
https://www.ncbi.nlm.nih.gov/pubmed/35846032
http://dx.doi.org/10.1002/jha2.380
work_keys_str_mv AT takahashihiromichi clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience
AT nishimakiharuna clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience
AT nakanishiyoko clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience
AT hamadatakashi clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience
AT nakagawamasaru clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience
AT iizukakazuhide clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience
AT uchinoyoshihito clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience
AT iriyamanoriyoshi clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience
AT miurakatsuhiro clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience
AT nakayamatomohiro clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience
AT masudashinobu clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience
AT hattayoshihiro clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience
AT nakamurahideki clinicalimpactofcentralnervoussystemdirectedtherapiesonintravascularlargebcelllymphomaasingleinstitutionsexperience

Ejemplares similares